scholarly journals Anti-Inflammatory Peptide Attenuates Edema and Promotes BMP-2-Induced Bone Formation in Spine Fusion

2018 ◽  
Vol 24 (21-22) ◽  
pp. 1641-1651 ◽  
Author(s):  
Juliane D. Glaeser ◽  
Khosrowdad Salehi ◽  
Linda E.A. Kanim ◽  
Dmitriy Sheyn ◽  
Zachary NaPier ◽  
...  
Bone Research ◽  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Tao Yu ◽  
Jianguo Zhang ◽  
Wei Zhu ◽  
Xiao Wang ◽  
Yun Bai ◽  
...  

AbstractAnkylosing spondylitis (AS) is chronic inflammatory arthritis with a progressive fusion of axial joints. Anti-inflammatory treatments such as anti-TNF-α antibody therapy suppress inflammation but do not effectively halt the progression of spine fusion in AS patients. Here we report that the autoimmune inflammation of AS generates a microenvironment that promotes chondrogenesis in spine ligaments as the process of spine fusion. Chondrocyte differentiation was observed in the ligaments of patients with early-stage AS, and cartilage formation was followed by calcification. Moreover, a large number of giant osteoclasts were found in the inflammatory environment of ligaments and on bony surfaces of calcified cartilage. Resorption activity by these giant osteoclasts generated marrow with high levels of active TGF-β, which induced new bone formation in the ligaments. Notably, no Osterix+ osteoprogenitors were found in osteoclast resorption areas, indicating uncoupled bone resorption and formation. Even at the late and maturation stages, the uncoupled osteoclast resorption in bony interspinous ligament activates TGF-β to induce the progression of ossification in AS patients. Osteoclast resorption of calcified cartilage-initiated ossification in the progression of AS is a similar pathologic process of acquired heterotopic ossification (HO). Our finding of cartilage formation in the ligaments of AS patients revealed that the pathogenesis of spinal fusion is a process of HO and explained why anti-inflammatory treatments do not slow ankylosing once there is new bone formation in spinal soft tissues. Thus, inhibition of HO formation, such as osteoclast activity, cartilage formation, or TGF-β activity could be a potential therapy for AS.


2009 ◽  
Vol 9 (10) ◽  
pp. 28S
Author(s):  
Hyun Bae ◽  
Vikas Patel ◽  
Ben Pradhan ◽  
Jeffrey Toth ◽  
Jeffrey Badura ◽  
...  

2019 ◽  
Vol 14 (1) ◽  
pp. 147-159 ◽  
Author(s):  
Slobodan Vukicevic ◽  
Lovorka Grgurevic ◽  
Igor Erjavec ◽  
Marko Pecin ◽  
Tatjana Bordukalo‐Niksic ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yong Xie ◽  
Meng Pan ◽  
Yanpan Gao ◽  
Licheng Zhang ◽  
Wei Ge ◽  
...  

AbstractThe failure of remodeling process that constantly regenerates effete, aged bone is highly associated with bone nonunion and degenerative bone diseases. Numerous studies have demonstrated that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) activate cytokines and mediators on osteoclasts, osteoblasts and their constituent progenitor cells located around the remodeling area. These cells contribute to a complex metabolic scenario, resulting in degradative or synthetic functions for bone mineral tissues. The spatiotemporal effects of aspirin and NSAIDs in the bone remodeling are controversial according the specific therapeutic doses used for different clinical conditions. Herein, we review in vitro, in vivo, and clinical studies on the dose-dependent roles of aspirin and NSAIDs in bone remodeling. Our results show that low-dose aspirin (< 100 μg/mL), which is widely recommended for prevention of thrombosis, is very likely to be benefit for maintaining bone mass and qualities by activation of osteoblastic bone formation and inhibition of osteoclast activities via cyclooxygenase-independent manner. While, the roles of high-dose aspirin (150–300 μg/mL) and other NSAIDs in bone self-regeneration and fracture-healing process are difficult to elucidate owing to their dual effects on osteoclast activity and bone formation of osteoblast. In conclusion, this study highlighted the potential clinical applications of low-dose aspirin in abnormal bone remodeling as well as the risks of high-dose aspirin and other NSAIDs for relieving pain and anti-inflammation in fractures and orthopedic operations.


2009 ◽  
Vol 19 (9) ◽  
pp. 287-290 ◽  
Author(s):  
Wasim Khan ◽  
Mamun Al-Rashid ◽  
David R Marsh

Non-steroidal anti-inflammatory drugs are powerful and effective anti-inflammatory, analgesic and anti-pyretic drugs. They are routinely used in orthopaedic conditions and in the perioperative setting. They are however associated with potentially life-threatening side-effects and it is important to appreciate these before these medicines are administered. There is evidence suggesting that these drugs adversely affect bone formation, and this has implications for their use in patients with fractures and other pathologies that involve bone remodelling.


1992 ◽  
Vol 27 (1) ◽  
pp. 28-33 ◽  
Author(s):  
Mohamadreza Yazdi ◽  
David T. Cheung ◽  
Stephanie Cobble ◽  
Marcel E. Nimni ◽  
Steven E. Schonfeld

Sign in / Sign up

Export Citation Format

Share Document